N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-oxo-1H-quinoline-4-carboxamide | 583881-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-oxo-1H-quinoline-4-carboxamide
• CAS: 583881-56-5
• 化学式: C₂₄H₂₅Cl₂N₃O₄
• 分子量: 490.386
• InChiKey: MAWNODXTLNGOAA-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  90.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4(3,4-二氯苯氧基)哌啶 在 sodium azide 、 三苯基膦 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-oxo-1H-quinoline-4-carboxamide
  参考文献：
  名称：

  Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I

  摘要：

  The discovery of potent small molecule dual antagonists of the human CCR3 and H-1 receptors is described for the treatment of allergic diseases, for example, asthma and allergic rhinitis. Optimizing in vitro potency and metabolic stability, starting from a CCR1 lead compound, led to compound 20 with potent dual CCR3/H-1 activity and in vitro metabolic stability. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.113

文献信息

• Chemical compounds
  申请人：Alcaraz Lilian

  公开号：US20050107428A1

  公开（公告）日：2005-05-19

  The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH 2 , O, S(O) 2 or NR 10 ; Y is a bond, CH 2 , NR 35 , CH 2 NH, CH 2 NHC(O), CH(OH), CH(NHCOR 33 ), CH(NHSO 2 R 34 ), CH 2 O or CH 2 S; Z is C(O), or when Y is a bond Z can also be S(O) 2 ; R 1 is optionally substituted aryl, optionally substituted heterocyclyl or C 4-6 cycloalkyl fused to a benzene ring; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , R 9 , R 10 , R 32 , R 33 , R 34 and R 35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

  该发明提供了式（I）的化合物：[化学式应在此处插入。请参见纸质副本]其中：X为CH2，O，S（O）2或NR10；Y为键，CH2，NR35，CH2NH，CH2NHC（O），CH（OH），CH（NHCOR33），CH（NHSO2R34），CH2O或CH2S；Z为C（O），或当Y为键时，Z也可以是S（O）2；R1是可选择的取代芳基，可选择的取代杂环基或与苯环融合的C4-6环烷基；R2、R3、R4、R5、R6、R7和R8、R9、R10、R32、R33、R34和R35如本文所定义；是趋化因子（特别是CCR3）活性调节剂（例如用于治疗哮喘）。该发明还提供了制备4-（3,4-二氯苯氧基）哌啶的方法，该方法有用于制备该发明的某些化合物的中间体。
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1478624A1

  公开（公告）日：2004-11-24
• US7709500B2
  申请人：——

  公开号：US7709500B2

  公开（公告）日：2010-05-04
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2003068743A1

  公开（公告）日：2003-08-21

  The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z isC(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl,optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein;are modulators of chemokine (especially CCR3) activity (for use in, for example,treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.
• Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I
  作者：Mark Furber、Lilian Alcaraz、Christopher Luckhurst、Ash Bahl、Haydn Beaton、Keith Bowers、John Collington、Rebecca Denton、David Donald、Elizabeth Kinchin、Cathy MacDonald、Aaron Rigby、Rob Riley、Matt Soars、Brian Springthorpe、Peter Webborn

  DOI：10.1016/j.bmcl.2012.09.113

  日期：2012.12

  The discovery of potent small molecule dual antagonists of the human CCR3 and H-1 receptors is described for the treatment of allergic diseases, for example, asthma and allergic rhinitis. Optimizing in vitro potency and metabolic stability, starting from a CCR1 lead compound, led to compound 20 with potent dual CCR3/H-1 activity and in vitro metabolic stability. (C) 2012 Elsevier Ltd. All rights reserved.